Californian Heart Disease Patient Shows Improvement After Stem Cell Therapy

Share Article

Improvement of California woman stuns her cardiologist one month after receiving stem cell treatment in Bangkok, Thailand.

Dee Coats, the first Californian to receive VesCell™ stem cell therapy for heart disease is featured in the September 1st issue of the Palo Verde Valley Times. The story, “Blythe woman’s trip to Bangkok repairs damaged heart” authored by Marty Bachman can be found on the Palo Verde Valley Times home page.

Coats is quoted as saying, “You feel so much better so quickly, its amazing, I do more and more every day. Now I can walk further than half a block without having to sit down and have a heart attack.”

Coats further noted that her cardiologist has re-classed her from a Class 3 to a Class 2 cardiac patient and is taking her off three of the medications she had been taking.

About VesCell™

VesCell™ uses a patient’s own adult stem cells to treat Heart Disease and is a viable alternative for patients who either cannot undergo or choose not to undergo the standard treatment such as Coronary Artery Bypass Grafting (CABG).

VesCell™ uses adult stem cells harvested from approximately ½ pint of the patients own blood to treat several heart conditions. Once harvested, the cells are differentiated and expanded in vitro at the TheraVitae Labs in Israel and are ready for implantation in about one week.

About TheraVitae

TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology called VesCell™ that is currently being used by hospitals in Thailand to treat patients with heart disease. TheraVitae is based in Bangkok, Thailand, Kiryat Weizmann, Israel, and Hong Kong.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay Lenner
TheraVitae, Ltd.
Email >